Management Team and Founders

R. Barry Holtz, Ph.D.
Chief Executive Officer (CEO)

The InterveXion management team is led by CEO R. Barry Holtz, PhD, a career entrepreneur who has been in the bio-products and biopharmaceutical field for 30 years and a founder of three successful companies. With Large Scale Biology Corporation, he was a founder, corporate officer and Senior Vice President for Biopharmaceutical Development, while leading the drug development activities of the company including: bio-manufacturing, clinical trials management, and regulatory affairs. Dr. Holtz managed a team that brought a recombinant dermatologic product, melanin, to market and also brought a patient-specific vaccine for Non-Hodgkin’s lymphoma successfully to the clinic and the beginning of a Phase 3 trial.

S. Michael Owens, Ph.D.
Chief Scientific Officer (CSO)

Professor and Director, Center for Alcohol and Drug Abuse, and a
Wilbur Mills Endowed Chair in Alcohol and Drug Abuse Prevention
University of Arkansas for Medical Sciences

S. Michael Owens, PhD, the Company’s Chief Scientific Officer, is a Professor of Pharmacology and Toxicology and holds a Wilbur Mills Endowed Chair in Alcohol and Drug Abuse Studies at UAMS. Dr. Owens has expertise in pharmacokinetics, pharmacodynamics and immunopharmacology with extensive experience in vaccine design and the development of therapeutic monoclonal antibodies. He pioneered the research and development of the therapeutic antibodies and vaccines for drug abuse that are the foundation for InterveXion.

W. Brooks Gentry, MD
Chief Medical Officer (CMO)

Professor of Anesthesiology and Pharmacology and Pharmacology & Toxicology
University of Arkansas for Medical Sciences

InterveXion’s Chief Medical Officer is W. Brooks Gentry, MD, who is currently a Professor of Anesthesiology and Pharmacology & Toxicology, and Vice-Chair for Research in the Department of Anesthesiology in the College of Medicine at UAMS. Dr. Gentry brings expertise in clinical trial design for therapeutic biologics, including monoclonal antibodies. He has performed human clinical and basic science research on drugs that affect the central nervous system (brain and spinal cord) since 1991.

Ralph Henry, Ph.D.
Vice President of Biopharmaceutics

Distinguished Professor of Biological Sciences
University of Arkansas, Fayetteville

Ralph Henry, PhD, a Distinguished Professor of Biological Sciences at the University of Arkansas, Fayetteville, is Vice President of Biopharmaceutics. Dr. Henry brings experience in molecular biology and molecular expression technology to InterveXion. He has a broad background in the expression of heterologous proteins in multiple systems, and molecular engineering of proteins.

Misty Stevens, Ph.D., MBA
Operations Director

Misty Ward Stevens, PhD, MBA is Operations Director for InterveXion with experience in protein biochemistry and cell culture, plus entrepreneurship. These skills allow her to conduct and oversee science operations at InterveXion and coordinate activities with commercial laboratories conducting the antibody manufacturing and testing. Furthermore, she has been involved in grant writing and administration, business plan and budget maturity, and patent filings.

Gerald A. Damerow
Chief Financial Officer

A former Ernst & Young partner, Gerald Damerow, CPA, serves as acting Chief Financial Officer. He is also a retired Associate Director of the UAMS BioVentures business accelerator.